Dexmedetomidine an Effective Drug in Reducing Anesthetic Requirements in External Dacrocystorhinostomy (DCR) Patients

Dexmedetomidine As an Effective Drug in Reducing Anesthetic Requirements in Patients Undergoing External Dacrocystorhinostomy, a Randomized Controlled Study

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06808295

Acronym

DCR

Enrollment

Registered

2025-02-05

Start date

2024-04-16

Completion date

2025-05-31

Last updated

2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assess Decreased Anesthetic Requirements Intraoperative, Patients Undergoing External Dacrocystorhinostomy Operations

Brief summary

Assessing the intra and postoperative hemodynamic stability in patients undergoing external dacrocystorhinostomy under general anesthesia using Dexmedetomidine as a preoperative sedation compared to traditional technique with intraoperative analgesia and assessing decreased anesthetic requirements intra and postoperative

Detailed description

Dexmedetomidine is a highly selective alpha 2 adrenoceptor agonist, having characteristics of natural sleep like sedation, can reduce pain intensity and opioid consumption without influencing the time of recovery from general anesthesia

Interventions

DRUGDexmedetomidine Hydrochloride

drug will be given before induction and anesthetic doses and hemodynamics will be assessed pre- intra and postoperative

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

SINGLE (Subject)

Intervention model description

2 Groups, Dexmedetomidine group and control group are assigned

Eligibility

Sex/Gender

ALL

Age

16 Years to 75 Years

Healthy volunteers

Inclusion criteria

patients of both sexes 16 years to 75 years of age ASA (American society of Anesthesiologists) I-III

Exclusion criteria

* Pediatric age group * ASA more than III

Design outcomes

Primary

Measure	Time frame	Description
Maintained hemodynamic values while reducing the anesthetic requirements	from 20 minutes after administering the drug till 2 hours after full recovery	Measuring the heart rate and the blod pressure every 5 minutes intraoperative and for half an hour postoperative to assess hemodynamic stability

Secondary

Measure	Time frame	Description
Delerium	from 20 minutes after administering the drug till 2 hours after full recovery	Reducing postoperative delirium in elderly patients

Countries

Egypt

Contacts

Primary ContactDina Moustafa Mohamed Ali, MD

dina.moustafa.ali@gmail.com01113981021

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026